In This Article:
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world. If you do not want to learn about the global biotech market, head straight to the 5 Biggest Biotechnology Companies in the World.
In the ever-evolving landscape of biotechnology, several companies like Novo Nordisk, Regeneron, and United Therapeutics, among others stand out for their innovative approaches and groundbreaking contributions to the field. These behemoths in biotech represent the forefront of scientific advancement, pioneering new therapies, diagnostics, and solutions to address pressing global challenges. From developing life-saving drugs to revolutionizing agricultural practices, the biggest biotechnology companies in the world play a pivotal role in shaping the future of healthcare, agriculture, and beyond.
Global Biotechnology Market Trends and Projections
The global biotechnology market is experiencing significant growth, with a projected value of USD 5.01 trillion by 2032. This market has been expanding rapidly due to various factors such as favorable government initiatives, plummeting sequencing prices, and increased demand for synthetic biology. Health-related applications have dominated the market, accounting for a substantial share in 2022. The market is characterized by key players like Johnson & Johnson (NYSE:JNJ) Services, Inc., F. Hoffmann-La Roche Ltd, Pfizer, and others.
Johnson & Johnson (NYSE:JNJ), a key player in healthcare, plans to split into two companies focused on pharmaceuticals, medical devices, and consumer products. Their groundbreaking single-dose COVID-19 vaccine underscores their commitment to innovation, despite challenges. The company's medtech growth strategy, including investments in robotics and strategic acquisitions, positions it as a leader in the sector. Johnson & Johnson (NYSE:JNJ)'s Q1 2024 financial report showed a 22% sales decline to $138.6 million, with a net income of $4 million. Despite the decrease, the gross margin increased to 38.1%, with no debt and active inventory reduction plans.
The U.S. biotechnology market size was USD 246.18 billion in 2023 and is projected to reach around USD 763.82 billion by 2033 with a CAGR of 11.90%. North America dominated the global biotechnology market in 2023 due to strong R&D initiatives and high healthcare expenses in the region. The U.S. market has seen significant contributions from major players and increased R&D activities, driving its growth trajectory. AstraZeneca PLC (NASDAQ:AZN), Gilead Sciences, Inc., Novo Nordisk A/S, and Abbott Laboratories are prominent companies driving innovation in therapeutics development within the biotechnology sector.
AstraZeneca PLC (NASDAQ:AZN), a global biopharmaceutical company, led by CEO Pascal Soriot and CFO Aradhana Sarin, focuses on innovative medicines, notably Tagrisso, a leading lung cancer treatment with sales exceeding $5.44 billion in 2022. Their pipeline includes Orpathys and Lynparza, expected to bolster lung cancer treatment. Despite a decline in COVID-19 medicine revenue, Q1 2024 saw a 6% total revenue increase to $45,811 million, with core EPS up by 15% to $7.26. AstraZeneca PLC (NASDAQ:AZN) anticipate FY 2024 revenue and core EPS to increase by a low double-digit to low teens percentage. AstraZeneca emphasizes ethical practices, sustainability, and inclusivity, investing $400 million in reforestation and making management changes. They've also announced collaborations for a novel RNA-based pandemic influenza vaccine and acquired Pfizer's early-stage rare disease gene therapy portfolio.
Illumina's Leadership in Genomic Advancements and the Future of Precision Medicine
In the realm of healthcare, genomic research and precision medicine have emerged as transformative forces, ushering in a new era where treatments are tailored to individual genetic profiles. Illumina, a leading figure in this field, has played a pivotal role in driving forward genomic progress through its innovative technologies and strategic collaborations. At the helm of this endeavor is Rami Mehio, the head of software and informatics at Illumina, whose contributions have been instrumental in spearheading major genomic initiatives such as the UK Biobank's whole-genome sequencing project.
One of Illumina's standout contributions lies in its DRAGEN pipeline, a groundbreaking technology that has revolutionized genomic data analysis by significantly enhancing sensitivity and precision in detecting genetic variants. Moreover, Illumina's collaborations with esteemed programs like the UK Biobank have facilitated large-scale whole-genome sequencing efforts, crucial for identifying rare variants associated with various diseases. Through strategic partnerships with research cohorts such as the All of Us program, Illumina has further accelerated drug discovery by leveraging genetic evidence to identify new drug targets.
Financially, Illumina has demonstrated a significant commitment to advancing genomic research. The company has made substantial investments in developing cutting-edge technologies like the DRAGEN pipeline. Notably, its support for the Precision Medicine Initiative, underscored by a $215 million investment in 2016, underscores its dedication to driving forward personalized healthcare.
Looking ahead, the future holds promise for even more precise medical treatments, particularly within the realm of synthetic biology. This advancement stands to have profound implications for drug discovery and disease management. However, it's essential to acknowledge the substantial financial investment required in pharmaceutical research and development. With the average pre-tax cost of developing a new drug or biologic standing at approximately $1.39 billion, the industry faces significant financial challenges.
The burgeoning field of genetic engineering, particularly advancements in gene-editing technologies, is poised to revolutionize healthcare by introducing new therapeutic categories such as cell therapy and gene editing. The genomic medicines industry is projected to grow substantially, with estimates suggesting it could reach $50 billion by 2028. Genomic sequencing technology, which has already transformed the healthcare industry, is anticipated to become more accessible, with the price per genome expected to decrease to $100 by 2025.
Despite the promise of gene therapy in treating previously intractable diseases, concerns about affordability persist due to the high prices of existing therapies. Nonetheless, gene therapy is expected to have a significant financial impact on the healthcare industry, with annual spending on approved therapies projected to reach $25.3 billion in 2026.
A close up photograph of a vial of a new biotechnological drug candidate in development.
Our Methodology
For our methodology, we have ranked the biggest biotechnology companies in the world based on their current market cap. For the accuracy of data, we relied on Finviz.
Here is the list of 30 biggest biotechnology companies in the world.
30. Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)
Market Cap: $5.38 billion
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a leading biotech company, gained FDA approval for Rezdiffra™ (resmethrin) for Noncirrhotic Nonalcoholic Steatohepatitis (NASH). Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)'s fiscal Q1 2024 financials show $68,605 in R&D expenses, and $17,845 in general and administrative expenses, resulting in a $86,450 loss from operations. Interest income was $3,551, and interest expense was $2,900.
29. Blueprint Medicines Corporation (NASDAQ:BPMC)
Market Cap: $5.54 billion
Blueprint Medicines Corporation (NASDAQ:BPMC) is one of the top biotech companies that specializes in precision therapies targeting genetic drivers, particularly in cancer treatment. They translate scientific discoveries into a diverse pipeline of promising therapies and have successfully delivered approved medicines for various cancers. In 2022, Blueprint Medicines Corporation (NASDAQ:BPMC)'s revenue reached $204.0 million, driven by sales of AYVAKIT/AYVAKYT and collaboration revenues.
28. CRISPR Therapeutics AG (NASDAQ:CRSP)
Market Cap: $6.14 billion
CRISPR Therapeutics AG (NASDAQ: CRSP) is renowned for its innovative therapies across various disease areas. The company's focus on CRISPR technology has led to groundbreaking advancements in treating genetic disorders and diseases. In Q1 2024, CRISPR Therapeutics AG (NASDAQ: CRSP) reported collaboration and grant revenue totaling $201.2 million, with a net income of $69.583 million.
27. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Market Cap: $6.20 billion
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a top biotechnology company in Carlsbad, California, specializes in RNA-targeted therapeutics, providing groundbreaking treatments for genetic disorders like SMA, hereditary transthyretin amyloidosis, and familial chylomicronemia syndrome. Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)'s innovative approach targets diseases at the genetic level, offering hope to patients with unmet medical needs. In fiscal year 2023, they reported a revenue of US$788.0 million, marking a notable 34% increase from the previous year.
26. Cytokinetics, Incorporated (NASDAQ:CYTK)
Market Cap: $6.71 billion
Cytokinetics, Incorporated (NASDAQ:CYTK) is a leading biopharmaceutical company focusing on muscle activators and inhibitors for debilitating diseases. Their key drug candidates include omecamtiv mecarbil, in Phase III trials for heart failure, and CK-136, a cardiac troponin activator. Cytokinetics, Incorporated (NASDAQ:CYTK)made significant contributions to healthcare by addressing muscle dysfunction-related conditions. In 2023, their revenue was $7.53 million, reflecting a notable decrease from the previous year.
25. Viking Therapeutics, Inc. (NASDAQ:VKTX)
Market Cap: $6.84 billion
Viking Therapeutics, Inc. (NASDAQ:VKTX), headquartered in San Diego, California is specializing in therapies for metabolic and endocrine disorders. They've developed several key drug candidates like VK2809 for non-alcoholic steatohepatitis (NASH), VK5211 for hip fracture recovery, and VK0612 for type 2 diabetes. In 2023, Viking Therapeutics, Inc. (NASDAQ:VKTX) reported a net loss of $24.6 million or $0.25 per share.
24. Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)
Market Cap: $6.84 billion
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is another one of the top biopharmaceuticals companies focused on innovative treatments for serious medical conditions. They've made significant strides in research and development, resulting in potential life-changing therapies. In 2023, Apellis Pharmaceuticals, Inc. (NASDAQ:APLS)'s preliminary total U.S. product revenues reached approximately $366 million.
23. Exelixis, Inc. (NASDAQ:EXEL)
Market Cap: $6.97 billion
Exelixis, Inc. (NASDAQ:EXEL) is a leading oncology biotech known for CABOMETYX and COMETRIQ for tough cancers. They innovate in renal cell carcinoma, thyroid cancer, and melanoma. Developing new meds like zanzalintinib and XB002. In Q3 2023, Exelixis, Inc. (NASDAQ:EXEL) had total revenues of $471.9M, and net product revenues of $426.5M.
22. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Market Cap: $7.54 billion
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is one of the biggest biotechnology companies in the world known for innovative pharmaceuticals in areas like oncology, neuroscience, and rare diseases. Their focus on cutting-edge treatments has positively impacted patient outcomes. In the first nine months of 2023, Jazz Pharmaceuticals plc (NASDAQ:JAZZ) reported revenue close to $3 billion. Earnings per share stood at $5.02, slightly below expectations.
21. Vaxcyte, Inc. (NASDAQ:PCVX)
Market Cap: $7.56 billion
Vaxcyte, Inc. (NASDAQ:PCVX), headquartered in San Carlos, California ISfocusing on high-fidelity vaccines for bacterial infectious diseases. Their flagship vaccine candidate, VAX-24, aims to prevent invasive pneumococcal disease with broad-spectrum coverage. They're also developing other vaccines like VAX-31 and VAX-A1 targeting various bacterial strains. In 2023, Vaxcyte, Inc. (NASDAQ:PCVX) reported total operating expenses of $468.041 million, with $332.341 million invested in research and development to advance vaccine development programs.
20. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)
Market Cap: $7.69 billion
Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE) is one of the biggest biotechnology companies in the world, specializing in therapies for neuroscience diseases such as schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder, and Parkinson’s disease. They focus on understanding disease biology to develop innovative treatments. Cerevel Therapeutics Holdings, Inc. (NASDAQ:CERE)'s pipeline includes promising candidates like Emraclidine, Darigabat, Tavapadon, and CVL-871, with ongoing or planned clinical trials, including Phase III trials for Parkinson's and Phase II trials for schizophrenia.
19. Roivant Sciences Ltd. (NASDAQ:ROIV)
Market Cap: $8.17 billion
Roivant Sciences Ltd. (NASDAQ:ROIV) stands nineteenth among the top biotech companies known for innovative contributions to healthcare. They've developed novel treatments across various therapeutic areas, positively impacting patient outcomes. In Q4 2023, Roivant Sciences Ltd. (NASDAQ:ROIV) reported an operating profit of 15,395 million CHF, with a net income of 12,358 million CHF. Core Pharmaceuticals sales reached 44,612 million CHF, while Diagnostics sales amounted to 14,104 million CHF.
18. Ascendis Pharma A/S (NASDAQ:ASND)
Market Cap: $8.42 billion
Ascendis Pharma A/S (NASDAQ:ASND), headquartered in Denmark is focusing on pharmaceutical products for various medical conditions globally. They've made significant contributions in areas like growth hormone deficiency and endocrinology, improving patient outcomes and addressing unmet medical needs. In Q4 2023, Ascendis Pharma A/S (NASDAQ:ASND)'s total investments amounted to $13,948,467, including $651,930 in the Consumer Staples sector and $5,338 in the healthcare sector.
17. United Therapeutics Corporation (NASDAQ:UTHR)
Market Cap: $11.10 billion
United Therapeutics Corporation (NASDAQ:UTHR) stands seventeenth among the biggest biotechnology companies in the world, known for its innovative pharmaceutical products, particularly in pulmonary arterial hypertension and infectious diseases. Their prostacyclin analogs like Remodulin, Tyvaso, and Orenitram are instrumental in treating pulmonary arterial hypertension. United Therapeutics Corporation (NASDAQ:UTHR) also develop engineered lungs for transplantation, showcasing pioneering approaches to healthcare challenges. In Q4 2023, their total revenues reached $614.7 million, with a net income of $217.1 million, reflecting strong financial performance.
16. Bio-Techne Corporation (NASDAQ:TECH)
Market Cap: $11.40 billion
Bio-Techne Corporation (NASDAQ:TECH) is one of the largest biotechnology companies known for its innovative contributions to healthcare through cutting-edge products and services. Their focus on research and development has facilitated advancements in genomics, proteomics, and drug discovery. With a total revenue of $1.14 billion as of the most recent quarter ending December 31, 2023, and healthy profit and operating margins of 19.58% and 18.39% respectively, Bio-Techne Corporation (NASDAQ:TECH) demonstrates strong financial performance and operational efficiency.
15. Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
Market Cap: $11.55 billion
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is known for pioneering treatments for rare genetic diseases, particularly Duchenne muscular dystrophy (DMD) and neuromuscular disorders. Their innovative therapies aim to improve patient's quality of life. With a strong focus on research and development, Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has made substantial advancements in biotechnology, addressing unmet medical needs and positioning itself as a key player in the healthcare industry.
14. Legend Biotech Corporation (NASDAQ:LEGN)
Market Cap: $11.64 billion
Legend Biotech Corporation (NASDAQ:LEGN) is a notable player in the biotech industry, specializing in innovative cell therapies for oncology and other indications. With global operations, particularly in the US and China, Legend Biotech Corporation (NASDAQ:LEGN) has received FDA approval for its CAR-T therapy, a significant advancement in cancer treatment, especially for relapsed and refractory multiple myeloma patients. In Q4 2023, license revenue was $35.2 million, down from $50.0 million in 2022, while collaboration revenue reached $249.8 million.
13. Karuna Therapeutics, Inc. (NASDAQ:KRTX)
Market Cap: $12.60 billion
Karuna Therapeutics, Inc. (NASDAQ:KRTX) is one of the biggest biotechnology companies in the world, focusing on transformative medicines for psychiatric and neurological conditions. Their lead product candidate, KarXT, shows promise in treating acute psychosis in adults with schizophrenia and psychosis in Alzheimer's disease. They're also developing KAR-2618 for mood and anxiety disorders. In Q4 2023, Karuna Therapeutics, Inc. (NASDAQ:KRTX) reported a net loss of $113.8 million, reflecting investments in research and development.
12. Incyte Corporation (NASDAQ:INCY)
Market Cap: $13.11 billion
Incyte Corporation (NASDAQ:INCY) is another top biopharmaceutical company known for innovative treatments like Jakafi and Opzelura. Jakafi has been pivotal in treating hematologic conditions and improving patients' quality of life, while Opzelura shows promise in addressing dermatologic disorders. Incyte Corporation (NASDAQ:INCY) has demonstrated impressive revenue growth, with total revenues increasing from $2.99 billion in 2021 to $3.70 billion in 2023. Product revenues have also risen steadily, with Jakafi's net revenues reaching $2.6 billion in 2023, and Opzelura showing robust growth with net product revenues of $109 million in Q4'23 and $338 million for FY'23.
11. Royalty Pharma plc (NASDAQ:RPRX)
Market Cap: $13.44 billion
Royalty Pharma plc (NASDAQ:RPRX), founded in 1996, acquires biopharmaceutical royalties and funds innovation in the sector. They support treatments like Spinraza and olpasiran through strategic acquisitions and co-funding late-stage trials. Royalty Pharma plc (NASDAQ:RPRX)'s portfolio includes royalties on over 35 products and 14 development-stage candidates. Portfolio Receipts for 2024 are estimated at $2.6-2.7 billion, with a 5-9% growth. Interest payments for the year are around $160 million, with $79 million projected for Q1 2024.
10. BioMarin Pharmaceutical Inc (NASDAQ:BMRN)
Market Cap: $15.82 billion
Established in 1997, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) is based in San Rafael, CA, specializing in genetic disorder treatments like PKU, CLN2 disease, MPS, and achondroplasia. Their mRNA therapies offer life-sustaining proteins for rare disorders. Q1 2024 saw total revenues rise to $646.2 million, up 20% year-over-year. Anticipating double-digit revenue growth and non-GAAP operating margin expansion, BioMarin Pharmaceutical Inc (NASDAQ:BMRN) aims for $2.7 billion in total revenues for 2024.
9. BeiGene, Ltd. (NASDAQ:BGNE)
Market Cap: $16.25 billion
BeiGene, Ltd. (NASDAQ:BGNE) is one of the largest biotech companies in the world, known for innovative oncology treatments. In Q4 2023, they reported $630.5M in product revenue with an 83.2% gross margin. Full-year revenue was $2.2B with an 82.7% gross margin. BeiGene, Ltd. (NASDAQ:BGNE)'s operating expenses were $912.4M (GAAP) in Q4 and $3.3B (GAAP) for the year.
8. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)
Market Cap: $18.80 billion
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is known for its innovative RNA interference (RNAi) therapeutics, targeting specific genes to address genetic diseases at their root cause. With a robust pipeline and multi-product commercial portfolio, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a key player in the industry. In 2023, company's net product revenues reached $1.24 billion, marking a significant 39% growth.
7. Genmab A/S (NASDAQ:GMAB)
Market Cap: $19.57 billion
Genmab A/S (NASDAQ:GMAB), a Danish biotech leader, has specialized in innovative cancer antibody therapies since 1999. They develop cutting-edge platforms like bispecific T-cell engagers. With 20+ partnerships, they expand globally. Genmab A/S (NASDAQ:GMAB) aims to transform patient lives by 2030. Q1 2024 revenue surged 35% to DKK 2,854 million, boosted by royalties from Janssen and Novartis collaborations, and reimbursement from BioNTech SE.
6. BioNTech SE (NASDAQ:BNTX)
Market Cap: $21.98 billion
BioNTech SE (NASDAQ:BNTX), founded in 2008 in Mainz, Germany, stands sixth among the biggest biotechnology companies in the world, known for its contributions to healthcare, notably in immunotherapy. Their mRNA technology was pivotal in developing the Pfizer-BioNTech COVID-19 vaccine, aiding the global fight against the pandemic. In Q3 2023, BioNTech SE (NASDAQ:BNTX)'s revenues reached €895.3 million, with commercial revenues at €893.7 million and research & development revenues at €1.6 million.
Click to see and continue reading the 5 Biggest Biotechnology Companies in the World.
Suggested Articles:
Disclosure. None: The 30 Biggest Biotechnology Companies in the World is originally published on Insider Monkey.